Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
CCR5 drives NK cell–associated airway damage in pulmonary ischemia-reperfusion injury
Jesse Santos, … , John R. Greenland, Daniel R. Calabrese
Jesse Santos, … , John R. Greenland, Daniel R. Calabrese
Published October 3, 2023
Citation Information: JCI Insight. 2023;8(21):e173716. https://doi.org/10.1172/jci.insight.173716.
View: Text | PDF
Research Article Pulmonology Transplantation

CCR5 drives NK cell–associated airway damage in pulmonary ischemia-reperfusion injury

  • Text
  • PDF
Abstract

Primary graft dysfunction (PGD) limits clinical benefit after lung transplantation, a life-prolonging therapy for patients with end-stage disease. PGD is the clinical syndrome resulting from pulmonary ischemia-reperfusion injury (IRI), driven by innate immune inflammation. We recently demonstrated a key role for NK cells in the airways of mouse models and human tissue samples of IRI. Here, we used 2 mouse models paired with human lung transplant samples to investigate the mechanisms whereby NK cells migrate to the airways to mediate lung injury. We demonstrate that chemokine receptor ligand transcripts and proteins are increased in mouse and human disease. CCR5 ligand transcripts were correlated with NK cell gene signatures independently of NK cell CCR5 ligand secretion. NK cells expressing CCR5 were increased in the lung and airways during IRI and had increased markers of tissue residency and maturation. Allosteric CCR5 drug blockade reduced the migration of NK cells to the site of injury. CCR5 blockade also blunted quantitative measures of experimental IRI. Additionally, in human lung transplant bronchoalveolar lavage samples, we found that CCR5 ligand was associated with increased patient morbidity and that the CCR5 receptor was increased in expression on human NK cells following PGD. These data support a potential mechanism for NK cell migration during lung injury and identify a plausible preventative treatment for PGD.

Authors

Jesse Santos, Ping Wang, Avishai Shemesh, Fengchun Liu, Tasha Tsao, Oscar A. Aguilar, Simon J. Cleary, Jonathan P. Singer, Ying Gao, Steven R. Hays, Jeffrey A. Golden, Lorriana Leard, Mary Ellen Kleinhenz, Nicholas A. Kolaitis, Rupal Shah, Aida Venado, Jasleen Kukreja, S. Sam Weigt, John A. Belperio, Lewis L. Lanier, Mark R. Looney, John R. Greenland, Daniel R. Calabrese

×

Figure 4

CCR5+ NK cells are increased during mouse HC and express markers of maturity and tissue residence.

Options: View larger image (or click on image) Download as PowerPoint
CCR5+ NK cells are increased during mouse HC and express markers of matu...
We performed HC (n = 5) and sham (S, n = 5) procedures and quantified NK cells and their phenotypes via spectral flow cytometry across blood, spleen, thoracic lymph node (LN), and lung tissues collected 4 hours after reperfusion. (A) Contour plot of CCR1 on NK (CD45+CD3–F480–CD19–NK1.1+NKp46+) cells in the lung. (B) CCR1 frequency of total NK cells during HC or S procedures. (C) Histograms of CCR1 on NK cells with fluorescence minus one (FMO) control, HC, and S. (D) CCR1 on NK cells by median fluorescence intensity (MFI). (E) Contour plot of CCR5 on NK cells in the lung. (F) CCR5 frequency of total NK cells during HC or S procedures. (G) Histograms of CCR5 on NK cells with FMO control, HC, and S. (H) CCR5 on NK cells by MFI. (I–L) We quantified maturation states of CCR5+ and CCR5– NK cells. (M) Frequencies of CD49a on CCR5+ and CCR5– NK cells. (N) Heatmap of MFIs of additional markers of NK cell activation. Summary data are displayed with box-and-whisker plots illustrating individual data points, bound by boxes at 25th and 75th percentiles, and with medians depicted with bisecting lines. Differences were assessed using the Mann-Whitney U test with Benjamini-Hochberg corrections for multiple comparisons. *P < 0.05; **P < 0.01; ***P < 0.001.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts